

DAFTAR PUSTAKA

- Al-badawy, T.H., Mohamed, A., Abdel, M., dan Abdel, G., 2016. Predictive value of different scoring systems for critically ill patients with hospital acquired pneumonia. *Egyptian Journal of Chest Diseases and Tuberculosis*, **65**: 757–763.
- Aljufri, A.Q., Yasin, N.M., dan Wahyono, D., 2021. Rasionalitas Terapi Antibiotik Empiris Pada Pasien Pneumonia di Instalasi Rawat Inap RSUP Dr. Kariadi Semarang. *Majalah Farmaseutik*, **17**: 89.
- Almirall, J., Serra-Prat, M., Bolibar, I., dan Balasso, V., 2017. Risk Factors for Community-Acquired Pneumonia in Adults: A Systematic Review of Observational Studies. *Respiration*, **94**: 299–311.
- Alnimr, A., 2023. Antimicrobial Resistance in Ventilator-Associated Pneumonia: Predictive Microbiology and Evidence-Based Therapy. *Infectious Diseases and Therapy*, **12**: 1527–1552.
- American Thoracic Society, 2019. Top 20 Pneumonia Facts — 2019. *ATS*, 201.
- Baidya, S., Sharma, S., Mishra, S.K., Kattel, H.P., Parajuli, K., dan Sherchand, J.B., 2021. Biofilm Formation by Pathogens Causing Ventilator-Associated Pneumonia at Intensive Care Units in a Tertiary Care Hospital: An Armor for Refuge. *BioMed Research International*, **2021**: .
- Barrera, C.M., Mykietiuk, A., Metev, H., Nitu, M.F., Karimjee, N., Doreski, P.A., dkk., 2016. Efficacy and Safety of Oral Solithromycin versus Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia: A Global, Double-blind, Multicentre, Randomised, Active-controlled, Non-inferiority Trial (SOLITAIRE-ORAL). *The Lancet Infectious Diseases*, **16**: 421–430.
- Basilim, A., Wali, H., Rabaan, A.A., dan Eljaaly, K., 2022. Efficacy of Empiric Macrolides versus Fluoroquinolones in Community-Acquired Pneumonia Associated with Atypical Bacteria: A Meta-Analysis. *Respiratory Medicine and Research*, **82**: 1–5.
- Brunton, L.L., Hilal-Dandab, R., dan Knollmann, B.C., 2018. *Goodman & Gilman's: The Pharmacological Basis of Therapeutics*, 13th ed, The Routledge Companion to Aesthetics. McGraw Hill Education, USA.
- Charlson, M.E., Carrozzino, D., Guidi, J., dan Patierno, C., 2022. Charlson Comorbidity Index: A Critical Review of Clinimetric Properties. *Psychotherapy and Psychosomatics*, **91**: 8–35.
- Chisholm-Burns, M.A., Schwinghammer, T.L., Malone, P.M., Kolesar, J.M., Lee, K.C., dan Bookstaver, P.B., 2019. *Pharmacotherapy Principles and Practice*, 5th ed, McGraw Hill Education. McGraw Hill Education, USA.

- Choi, S.H., Cesar, A., Snow, T.A.C., Saleem, N., Arulkumaran, N., dan Singer, M., 2023. Respiratory Fluoroquinolone Monotherapy vs. β -Lactam Plus Macrolide Combination Therapy for Hospitalized Adults with Community-Acquired Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials. *International Journal of Antimicrobial Agents*, **62**: 106905.
- Chou, C.C., Shen, C.F., Chen, S.J., Chen, H.M., Wang, Y.C., Chang, W.S., dkk., 2019. Recommendations and guidelines for the treatment of pneumonia in Taiwan. *Journal of Microbiology, Immunology and Infection*, **52**: 172–199.
- Cilloniz, C., Martin-Loeches, I., Garcia-Vidal, C., Jose, A.S., dan Torres, A., 2016. Microbial etiology of pneumonia: Epidemiology, diagnosis and resistance patterns. *International Journal of Molecular Sciences*, **17**: .
- Cruz, C.S. Dela, Evans, S.E., Restrepo, M.I., Dean, N., Torres, A., Amara-Elori, I., dkk., 2021. Understanding the Host in the Management of Pneumonia: An Official American thoracic Society Workshop Report. *Annals of the American Thoracic Society*, **18**: 1087–1097.
- Dahlan, M., 2020. *STATISTIK Untuk Kedokteran Dan Kesehatan: Deskriptif, Bivariat, Dan Multivariat Dilengkapi Aplikasi Menggunakan SPSS*, 6th ed. Epidemiologi Indonesia, Jakarta.
- Damayanti, M., Olivianto, E., dan Yunita, E.P., 2022. Effects of Rational Use of Antibiotics on Clinical Improvement of Pediatric Inpatients with Pneumonia. *Indonesian Journal of Clinical Pharmacy*, **11**: 129–144.
- DiPiro, J.T., Yee, G.C., Posey, L.M., Haines, S.T., Nolin, T.D., dan Ellingrod, V., 2020. *Pharmacotherapy: A Pathophysiologic Approach*, 11th ed. USA.
- DirJen Pelayanan Kesehatan, 2021. *Panduan Penatagunaan Antimikroba Di Rumah Sakit*, 1st ed. Kemenkes RI, Indonesia.
- File, T.M., Rewerska, B., Vucinić-Mihailović, V., Gonong, J.R. V., Das, A.F., Keedy, K., dkk., 2016. SOLITAIRE-IV: A Randomized, Double-Blind, Multicenter Study Comparing the Efficacy and Safety of Intravenous-to-Oral Solithromycin to Intravenous-to-Oral Moxifloxacin for Treatment of Community-Acquired Bacterial Pneumonia. *Clinical Infectious Diseases*, **63**: 1007–1016.
- Fogarty, C., Siami, G., Kohler, R., File, T.M., Tennenberg, A.M., Olson, W.H., dkk., 2004. Multicenter, Open-Label, Randomized Study to Compare the Safety and Efficacy of Levofloxacin versus Ceftriaxone Sodium and Erythromycin Followed by Clarithromycin and Amoxicillin-Clavulanate in the Treatment of Serious Community-Acquired Pneumonia in Adul. *Clinical Infectious Diseases*, **38**: .
- Hammer, G.D. dan McPhee, S.J., 2019. *Pathophysiology of Disease: An Introduction to Clinical Medicine*, 8th ed, Mc Graw Hill Education. USA.

- Hardiana, I., Laksmiawati, D.R., Ramadaniati, H. utami, dan Sutarno, 2021. Evaluasi Penggunaan Antibiotika Pada Pasien Pneumonia Komunitas Di Instalasi Rawat Inap Rspad Gatot Subroto. *Majalah Farmasi dan Farmakologi*, **25**: 1–6.
- Horita, N., Otsuka, T., Haranaga, S., Namkoong, H., Miki, M., Miyashita, N., dkk., 2016. Beta-lactam plus Macrolides or Beta-Lactam Alone for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis. *Respirology*, **21**: 1193–1200.
- Izadi, M., Dadsetan, B., Najafi, Z., Jafari, S., Mazaheri, E., Dadras, O., dkk., 2018. Levofloxacin Versus Ceftriaxone and Azithromycin Combination in the Treatment of Community Acquired Pneumonia in Hospitalized Patient. *Recent Patents on Anti-Infective Drug Discovery*, **13**: .
- Joegijantoro, R., 2019. *Penyakit Infeksi*, Intimedia Kelompok Intrans Publishing. Intimedia Kelompok Intrans Publishing, Malang, Indonesia.
- Katzung, B.G., Kruidering-Hall, M., dan Trevor, A.J., 2019. *Katzung & Trevor's: Pharmacology Examination & Board Review*, 12th ed, Katzung & Trevor's pharmacology examination & board review. McGraw Hill Education, USA.
- Kementerian Kesehatan RI, 2013. *Pedoman Umum Penggunaan Antibiotik*, Pedoman Umum Penggunaan Antibiotik. Kemenkes RI, Indonesia.
- Kementerian Kesehatan RI, 2015. *Profil Kesehatan Dasar*. Indonesia.
- Kementerian Kesehatan RI, 2017. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Sepsis*.
- Kementerian Kesehatan RI, 2018. *Laporan Nasional RISKESDAS 2018*, Badan Penelitian dan Pengembangan Kesehatan.
- Kementerian Kesehatan RI, 2021. Pedoman Penggunaan Antibiotik. *Peraturan Menteri Kesehatan Republik Indonesia Nomor 28 Tahun 2021 tentang Pedoman Penggunaan Antibiotik*, 1–97.
- Kementerian Kesehatan RI, 2023. *Pedoman Nasional Pelayanan Kedokteran Tata Laksana Pneumonia Dewasa*, Kementerian Kesehatan RI. Jakarta.
- Kyprianou, M., Dakou, K., Aktar, A., Aouina, H., Behbehani, N., Dheda, K., dkk., 2023. Macrolides for Better Resolution of Community-Acquired Pneumonia: A Global Meta-Analysis of Clinical Outcomes with Focus on Microbial Aetiology. *International Journal of Antimicrobial Agents*, **62**: 106942.
- Lemeshow, S., Jr, D.W.H., Klar, J., dan Lwanga, S.K., 1990. *Adequacy of Sample Size in Health Studies*. World Health Organization (WHO), England.
- Lim, W.S., 2022. Pneumonia-Overview. *Encyclopedia of Respiratory Medicine*, **4**: 185–197.
- Liu, X., Zhou, H., Zhou, Y., Wu, X., Zhao, Y., Lu, Y., dkk., 2020. Risk Factors

Associated with Disease Severity and Length of Hospital Stay in COVID-19 Patients. *Journal of Infection*, **81**: e95–e97.

López-véjar, C.E., Cruz, L.C., Meraz-ortega, R., Román-flores, A., Geuguer-chávez, L., Pedro-gonzález, A., dkk., 2013. Effectiveness of Levofloxacin in NAC 2013 Medigraphic (Spanyol). *Med Int Mex*, **29**: 587–594.

Luna, C.M., Palma, I., Niederman, M.S., Membriani, E., Giovini, V., Wiemken, T.L., dkk., 2016. The Impact of Age and Comorbidities on the Mortality of Patients of Different Age Groups Admitted with Community-Acquired Pneumonia. *Annals of the American Thoracic Society*, **13**: 1519–1526.

Maratusholikhah, M., Subagio, Y., dan Hastuti, H., 2023. Hubungan Derajat Keparahan Pneumonia dengan Kejadian dan Waktu Terjadinya. *Medical Science and Hospital Management Journal*, **1**: 44–54.

Maret-Ouda, J., Panula, J., Santoni, G., Xie, S., dan Lagergren, J., 2023. Proton Pump Inhibitor Use and Risk of Pneumonia: A Self-Controlled Case Series Study. *Journal of Gastroenterology*, **58**: 734–740.

Meriyani, H., Sanjaya, D.A., Sutariani, N.W., Juanita, R.R.A., Siada, N.B., Farmasi, F., dkk., 2021. Penggunaan dan Resistensi Antibiotik di Instalasi Rawat Intensif Rumah Sakit Umum Daerah di Bali : Studi Ekologikal selama 3 Tahun Antibiotic Use and Resistance at Intensive Care Unit of a Regional Public Hospital in Bali : A 3-Year Ecological Study **10**: .

Metlay, J.P., Waterer, G.W., Long, A.C., Anzueto, A., Brozek, J., Crothers, K., dkk., 2019. Diagnosis and Treatment of Adults with Community-Acquired Pneumonia. *American Journal of Respiratory and Critical Care Medicine*, **200**: 45–67.

Milupi, M. dan Claybourn, L., 2020. *IV to Oral Switch & 5 Day Stop Policy*. NHS Doncaster and Bassetlaw Teaching Hospitals.

National Institute for Health and Care Excellent, 2022. *Pneumonia in Adults: Diagnosis and Management*, NICE Guideline.

Parmar, M.P., Kaur, M., Bhavanam, S., Mulaka, G.S.R., Ishfaq, L., Vempati, R., dkk., 2023. A Systematic Review of the Effects of Smoking on the Cardiovascular System and General Health. *Cureus*, **15**: .

Perhimpunan Dokter Paru Indonesia, 2014. *PNEUMONIA KOMUNITAS: Pedoman Diagnosis & Penatalaksanaan Di Indonesia*. Badan Penerbit FKUI, Jakarta.

Perhimpunan Dokter Paru Indonesia, 2021. *Panduan Umum Praktek Klinis Penyakit Paru Dan Pernapasan*. PDPI, Indonesia.

Peters, Z., Ashman, J.J., Schwartzman, A., dan DeFrances, C.J., 2022. National Hospital Care Survey Demonstration Projects: Examination of Inpatient Hospitalization and Risk of Mortality Among Patients Diagnosed With

Pneumonia.

Postma, D.F., van Werkhoven, C.H., van Elden, L.J.R., Thijsen, S.F.T., Hoepelman, A.I.M., Kluytmans, J.A.J.W., dkk., 2015. Antibiotic Treatment Strategies for Community-Acquired Pneumonia in Adults. *New England Journal of Medicine*, **372**: 1312–1323.

Raz-Pasteur, A., Shasha, D., dan Paul, M., 2015. Fluoroquinolones or Macrolides Alone versus Combined with β -lactams for Adults with Community-Acquired Pneumonia: Systematic Review and Meta-Analysis. *International Journal of Antimicrobial Agents*, **46**: 242–248.

Salsabila, N.N., Indraswari, N., dan Sujatmiko, B., 2022. Gambaran Kebiasaan Merokok Di Indonesia Berdasarkan Indonesia Family Life Survey 5 (Ifs 5). *Jurnal Ekonomi Kesehatan Indonesia*, **7**: 13.

Sitong, L., Tong, X., Ma, Y., Wang, D., Huang, J., Zhang, L., dkk., 2019. Respiratory Fluoroquinolones Monotherapy vs. β -Lactams with or without Macrolides for Hospitalized Community-Acquired Pneumonia Patients: A Meta-Analysis. *Frontiers in Pharmacology*, **10**: .

Sukriya, Manggau, M.A., dan Djaharuddin, I., 2022. Evaluasi Penggunaan Terapi Antibiotik Empiris Terhadap Luaran Klinis Pasien Pneumonia Komunitas Rawat Inap **26**: 19–25.

Tambun, S.H., Puspitasari, I., dan Safitri, I., 2019. Evaluasi Luaran Klinis Terapi Antibiotik pada Pasien Community Acquired Pneumonia Anak Rawat Inap. *Jurnal Manajemen dan Pelayanan Farmasi*, **9**: 213–224.

Tnesi, M.T., Permata, A., Aprilianti, R.G., dan Choirunniswah, J., 2023. Evaluasi Penggunaan Antibiotik pada Pasien Pneumonia di Rumah Sakit X Kota Malang. *Indonesian Journal of Pharmaceutical Education*, **3**: 413–420.

Uematsu, H., Yamashita, K., Kunisawa, S., dan Imanaka, Y., 2021. Prediction Model for Prolonged Length of Stay in Patients with Community-Acquired Pneumonia Based on Japanese Administrative Data. *Respiratory Investigation*, **59**: 194–203.

Wu, D., Wu, C., Zhang, S., dan Zhong, Y., 2019. Risk Factors of Ventilator-Associated Pneumonia in Critically Ill Patients. *Frontiers in Pharmacology*, **10**: 1–7.

Xu, L.Y., Wang, C.C., Peng, X.X., Jiao, Y., Zhao, C.Z., Zhang, L., dkk., 2022. Empirical Antibiotic Treatment Strategies for Community-Acquired Pneumonia: A Network Meta-analysis. *Journal of Global Antimicrobial Resistance*, **30**: 1–9.

Yadegarynia, D., Tehrani, S., Nejad, F.M., Shojaeian, F., dan Keyvanfar, A., 2022. Levofloxacin versus ceftriaxone and azithromycin for treating community-acquired pneumonia: a randomized clinical trial study. *Iranian Journal of Microbiology*, **14**: 458–465.

Yoon, C., Park, S.Y., Kim, B., Kwon, K.T., Ryu, S. yeol, Wie, S.H., dkk., 2022.
Relationship between The Appropriateness of Antibiotic Treatment and
Clinical Outcomes/Medical Costs of Patients with Community-Acquired
Acute Pyelonephritis: A Multicenter Prospective Cohort Study. *BMC
Infectious Diseases*, **22**: 1–11.